Plan Nacional De Prevención Control Y Seguimiento De Cáncer De Cuello Uterino

Objectives

The National Plan for Prevention, Control and Follow-up of Cervical Cancer 2009–2015 provides Bolivia’s framework for reducing cervical-cancer morbidity and mortality among women, particularly those aged 25 to 64, through a rights-based, universal and intercultural health approach.[1][2][3][4]It aligns with the National Policy on Family, Community and Intercultural Health and seeks to make prevention, detection, diagnosis, treatment and follow-up available through the National Health System.[2][3]

• Reduce cervical-cancer incidence, prevalence and mortality through strengthened prevention, timely detection, treatment and case follow-up.[5]
• Promote health, prevention and public awareness while respecting cultural diversity and reducing economic, social, cultural and geographical barriers to services.[6][5][7]
• Provide annual Papanicolaou screening and treatment of pre-malignant lesions up to carcinoma in situ through the Universal Maternal and Child Insurance package.[8]
• Inform communities and health providers, develop qualified human resources, strengthen service capacity, improve health information, promote research, and reinforce community and social oversight.[9][10][11][12]
• Organise action around information, education, training and awareness; human-resource development; facility equipment and strengthening; and health information and communication.[10][11][12]
• Target women aged 25 to 64, limit screening to two Papanicolaou tests per woman during the five-year plan, and aim for total screening coverage above 50%.[4]

The plan responds to a substantial national burden: cervical cancer was reported as having the highest mortality rate in the Americas, at 26.3 deaths per 100,000 women, and the second-highest incidence rate, at 56.55 cases per 100,000 women.[13]It identifies inadequate screening and follow-up coverage, poor information, limited training, weak laboratory organisation, and insufficient allocation of resources as barriers requiring a stronger national response.[5][7]

Implementation

Implementation uses a continuum-of-care model within the National System of Family, Community and Intercultural Health, connecting health establishments, municipal health networks and referral services from prevention and screening through diagnosis, treatment and follow-up.[6]The Ministry of Health and Sports leads policy, planning, regulation, coordination and oversight, while the General Directorate of Health Services, Directorate for Health Services Development, and Health Services and Quality Unit support implementation and compliance.[8][6]

• Coordinate national health authorities, departmental health services, health networks, hospitals and facilities, laboratories, municipalities, universities, health schools, social and community organisations, international agencies, and public, private and non-governmental providers.[1][2][10][11][12]
• Disseminate legal screening provisions, produce culturally appropriate information materials in different formats and languages, train personnel in communication, and hold periodic analysis meetings with social organisations.[3][10]
• Update national standards, protocols and procedures; train personnel in sampling, Papanicolaou testing, visual inspection with acetic acid, cytology, colposcopy and treatment; and incorporate cervical-cancer interventions into university and health-school curricula and clinical practice.[11]
• Equip facilities for Papanicolaou testing and visual inspection with acetic acid, ensure reference hospitals can provide colposcopy, biopsy and treatment of pre-neoplastic and in-situ lesions, and expand diagnostic and treatment capacity as screening coverage increases.[12][14][15]
• Establish standardised referral and counter-referral arrangements, including systems to trace women with positive biopsy diagnoses and referral pathways for invasive carcinoma.[7][12][16]
• Strengthen laboratory quality control, qualified staffing in reference cytology centres, and logistics for transporting samples and returning results.[7][17]

The plan strengthens the National Health Information System by incorporating cervical-cancer variables, registering screened women in family health records, and enabling health-network staff and laboratories to collect, analyse, use and transmit information.[16]It provides for a national monitoring instrument, periodic analysis of results, a mid-term evaluation and a final evaluation in 2015.[16]Monitoring includes screening coverage, sample adequacy, cytological and visual-inspection results, diagnostic and treatment follow-up, post-treatment complications, incidence and mortality.[18][4]Specified quality standards include no more than 10% inadequate samples, 1% to 5% high-grade cytological lesions, 5% to 25% positive visual inspection with acetic acid results, no more than 1% post-treatment complications, and no more than 5% of Papanicolaou tests conducted outside the target population.[18][4]

Community surveillance networks are intended to involve communities in information analysis, priority-setting, planning, supervision and evaluation, alongside social control of cervical-cancer activities.[19][18]The plan also calls for scientific research, including human papillomavirus typing and development of a strategy to incorporate human papillomavirus vaccination into the health system.[19]No explicit programme budget, detailed costing, funding source, financing gap or resource-mobilisation plan is specified, although the plan identifies requirements for training, information materials, equipment, infrastructure, laboratories, referrals and treatment.[10][11][12][16][19][18]

Monitoring & Evaluation

The Plan establishes a monitoring, surveillance and evaluation framework to track implementation, service quality, screening coverage, clinical follow-up and population-level impact on cervical-cancer morbidity and mortality. It combines strengthened health information systems, periodic performance analysis, formal mid-term and final evaluations, and community-based social oversight.[9][16][18][4]

• Strengthen the National Health Information System by incorporating cervical-cancer variables, registering screened women in family health records, supporting health-network staff to collect, analyse, use and transmit data, and tracing patients with positive biopsy diagnoses.[16]
• Implement a national monitoring instrument, conduct periodic analysis of results, undertake a mid-term evaluation, and complete a final evaluation in 2015.[16]
• Monitor implementation outputs including information materials produced and used, personnel trained, meetings completed, national standards updated and disseminated, training workshops delivered, and educational institutions integrating cervical-cancer detection and control methods into curricula and clinical practice.[10][11]
• Assess service readiness through the number and proportion of facilities with supplies, infrastructure and equipment for Papanicolaou testing, visual inspection with acetic acid, colposcopy, biopsy, and treatment of pre-neoplastic and in-situ lesions.[12]
• Track referral-system performance through the number of invasive-carcinoma patients referred, and improve case follow-up through standardised referral, counter-referral, registration and information systems.[7][12]
• Measure screening coverage among women aged 25 to 64, including first-time screening and screening within the target population, over 2009 to 2015.[18]
• Assess screening quality using inadequate sample rates, cytological findings and positive visual inspection with acetic acid results; stated standards are no more than 10% inadequate samples, 1 to 5% high-grade cytological lesions, and 5 to 25% positive visual inspection with acetic acid results.[18]
• Monitor diagnostic and treatment quality through low-grade squamous intraepithelial lesion results, positive visual inspection with acetic acid results, colposcopy-histology correlation, post-treatment complications, and Papanicolaou tests undertaken outside the target population.[4]
• Apply standards of no more than 1% for post-treatment complications and no more than 5% for Papanicolaou tests taken outside the target population.[4]
• Track follow-up through the proportions of women with positive Papanicolaou or visual inspection with acetic acid results who receive biopsy, women with pre-neoplastic lesions or cervical cancer who receive treatment, and women followed after treatment.[4]
• Measure impact using cervical-cancer mortality, incidence per 100,000 women aged 25 to 64, and incidence of high-grade lesions.[4]
• Use community surveillance networks, district participation in community analysis, epidemiological notification and records, and trained departmental surveillance teams to support accountability and local oversight.[18]

Baseline performance information highlights substantial weaknesses in the collection, analysis and use of service data, alongside insufficient indicators and submissions to the National Health Information System for decision-making.[7]National reporting recorded 312,374 Papanicolaou tests in 2007, but coverage among women aged 25 to 64 was 11.6%; this represented samples taken rather than women receiving cytology results.[17]The Plan identifies 80% risk-age population coverage as the international standard associated with significant results, while its own target is total coverage above 50% and no more than two Papanicolaou tests per woman during the five-year period.[17][4]

Projected monitoring data anticipate that national positive Papanicolaou results will rise as coverage expands, from 6,142 at 5% annual coverage to 21,760 at 35% annual coverage in the 2009 to 2015 projections.[15]Separate departmental projections show national positive-test totals rising from 1,536 in 2009 to 5,440 in 2015.[20]The Plan promotes social control and community surveillance, but does not specify reporting schedules, detailed evaluation methodologies, enforcement procedures, or accountability consequences beyond assigned institutions, indicators and review activities.[9][10][11][12]

Costing & Financing

The Plan identifies substantial resource needs for prevention, screening, diagnostics, treatment, information systems, laboratory services, referral pathways and workforce development, but does not provide an explicit programme budget, costed implementation plan, funding-gap estimate, financing-source breakdown, resource-mobilisation target or quantified economic assumptions.[10][11][12][16][19][18]

• Maintain universal maternal and child insurance coverage for annual cervical screening and treatment of pre-malignant lesions up to carcinoma in situ, without quantifying the financial resources attached to this entitlement.[8][3]
• Recognise prevention and early detection as relatively economical, while noting the high social and economic cost associated with cervical cancer without quantifying either cost.[6][5][13]
• Address insufficient resource allocation and limited availability of trained personnel, which are identified as constraints on the national response.[5]
• Resource information materials, multilingual communication, workforce training, updated protocols, facility equipment and supplies, reference laboratories, colposcopy, biopsy, treatment, referral services, surveillance and research activities.[10][11][12][16][19]
• Expand human resources, colposcopy, histological assessment and treatment capacity in proportion to increased screening coverage and the resulting increase in abnormal findings.[14][15][20]

Operational projections include an illustrative staffing assumption that each cytologist reads 40 Papanicolaou tests per working day, but no salary, unit-cost, investment, recurrent-cost or financial valuation is supplied.[21]The available material therefore supports identification of resource requirements and service-capacity pressures, rather than an assessment of affordability, fiscal sustainability or financing gaps.[14][15][20]